CareDx (CDNA) has been in focus after CEO John Hanna sold 19,480 shares under a Rule 10b5-1 plan, alongside fresh quarterly results showing 25% Q4 revenue growth and a new collaboration with 10x Genomics.

The recent 39.13% 3 month share price return, alongside a 7.37% 1 month move, suggests momentum has picked up again. However, the 1 year total shareholder return of an 11.80% decline and 5 year total shareholder return of a 76.84% decline highlight how tough the longer journey has been.

If CareDx’s update has you looking across transplant and diagnostics, it could be a useful moment to scan other healthcare stocks that might fit your watchlist next.

With revenue growth running at 10.78% annually and the share price still down 76.84% over five years, investors are left asking a simple question: is CareDx now a mispriced recovery story, or is the market already factoring in future growth?

Most Popular Narrative: 10.7% Undervalued

CareDx’s most followed valuation story points to a fair value of $23 per share versus the last close at $20.55, putting the spotlight on what is driving that gap.

The fair value estimate has risen slightly from 21.83 dollars to 23.00 dollars per share, reflecting a modestly higher intrinsic value assessment. The discount rate has increased slightly from 6.78% to about 7.08%, implying a marginally higher required return and risk assumption.

Curious what sits behind that higher fair value with a higher discount rate at the same time? Revenue, margins and a richer future earnings multiple all play a part. The full narrative explains how these pieces fit together and what would need to happen financially for CareDx to close that pricing gap.

Result: Fair Value of $23 (UNDERVALUED)

However, this hinges on reimbursement and policy staying supportive, since tighter LCD rules or bundled payments could pressure test volumes and leave that higher P/E feeling stretched.

Another Angle: Multiples Tell a Different Story

While the narrative fair value points to CareDx as 10.7% undervalued, the current P/E of 15x looks less generous against an SWS fair ratio of 6.5x, even though it sits below the US Biotechs average of 20.3x and peer average of 47.8x. That mix of apparent upside and fair ratio warning raises a simple question: is this a valuation cushion or a value trap?

Build Your Own CareDx Narrative

If you see the numbers differently, or prefer to test your own assumptions against the data, you can build a fresh view in minutes with Do it your way.

A great starting point for your CareDx research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If you stop with just one stock, you could miss other opportunities entirely, so take a few minutes to scan these focused idea lists and broaden your watchlist.

• Seek out income potential by checking these 12 dividend stocks with yields > 3% that might help you build more consistent cash returns into your portfolio.
• Tap into future tech themes by reviewing these 24 AI penny stocks that are plugged into artificial intelligence trends across different industries.
• Hunt for potential mispricings by scanning these 875 undervalued stocks based on cash flows that could offer more attractive entry points based on cash flow metrics.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.